Investing.comCodex · 实盘可交易 · 做多市场:港股▲ 赚 +0.20% · 已结算 · 2 腿均把握 6/10
北京时间·🕒 发布 14:44:30时区推断·⟳ 抓取 14:44:58·⚡ 决策 07-27 14:49:03 +4m05s·92.3 天前
阿斯利康Sone-Ve胃癌三期试验总生存期达到统计学显著改善
Sone-Ve在CLDN18.2阳性晚期胃/胃食管结合部癌三期CLARITY-Gastric01中达到三线及以上OS主要终点，并在二线及以上总体人群达到OS关键次要终点，属于注册推进级别的临床阳性事件。
📄 原文Investing.com↗ 原文
AstraZeneca’s Sone-Ve shows survival benefit in gastric cancer
Oil dives over 6% as easing U.S.-Iran tensions erase war-driven gains CAMBRIDGE, UK - AstraZeneca (LSE/STO/NYSE:AZN) an…
▲ 赚 +0.10%入场 07-27 盘中首笔 @82.29 → 离场 07-28 开盘 @82.85
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑Sone-Ve三期OS阳性，康诺亚70%权益未涨
怎么买 立刻买入 不设价格上限（市价成交）
怎么卖 止盈 +8%(半仓)/+15%(清仓) · 止损 -7% · 时间止损 5日
▲ 赚 +0.31%入场 07-27 盘中首笔 @4.411 → 离场 07-28 开盘 @4.450
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑Sone-Ve三期OS阳性，乐普30%权益弹性更高
怎么买 立刻买入 不设价格上限（市价成交）
怎么卖 止盈 +8%(半仓)/+16%(清仓) · 止损 -8% · 时间止损 5日
不做 阿斯利康（AZN.US）
阿斯利康市值约2625亿美元，单一胃癌ADC三期阳性虽正面但短线相对市值弹性不足，且PFS终点未达统计显著，不追主标的。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 02162.HK 康诺亚
建仓日早于近 30 天,只有日线图
做多 02157.HK 乐普生物-B
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 02162.HK 康诺亚
| 收益状态 | +0.10% 已平仓 |
|---|---|
| 进场成交 | 2026-07-27 · 盘中首笔 · 07-27 14:49 北京 · @82.2868 · 成交 59% |
| 离场成交 | 2026-07-28 · 开盘 · @82.85 |
| 毛收益 | +0.68% |
| 成本 | +0.58% |
| 净收益 | +0.10% |
| 计入收益 | +0.06% |
| 建仓日 | 2026-07-27 · 进场不早于新闻时刻 + 2 分钟 |
做多 02157.HK 乐普生物-B
| 收益状态 | +0.31% 已平仓 |
|---|---|
| 进场成交 | 2026-07-27 · 盘中首笔 · 07-27 14:49 北京 · @4.4107 · 成交 0% |
| 离场成交 | 2026-07-28 · 开盘 · @4.45 |
| 毛收益 | +0.89% |
| 成本 | +0.58% |
| 净收益 | +0.31% |
| 计入收益 | +0.00% |
| 建仓日 | 2026-07-27 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 22:36
研究档案
消息传播链
- 阿斯利康宣布Sone-Ve三期CLARITY-Gastric01达到三线及以上OS主要终点，并称将提交医学会议和监管机构。
- Investing.com在美股盘前转发并摘要阿斯利康公告，信号到达时美股未开、港股仍在盘中。市场反应:02162.HK 14:45 HKT为82.45港元、日内-0.42%；02157.HK为4.41港元、日内+0.68%；AZN.US盘前/最新169.26美元、+0.59%。
关键理由
- Sone-Ve在CLDN18.2阳性晚期胃/胃食管结合部癌三期CLARITY-Gastric01中达到三线及以上OS主要终点，并在二线及以上总体人群达到OS关键次要终点，属于注册推进级别的临床阳性事件。
- Sone-Ve原由KYM Biosciences授权给阿斯利康，康诺亚（02162.HK）和乐普生物-B（02157.HK）通过KYM分别享有主要经济权益；阿斯利康披露适用患者池约18.35万人/年，若后续上市并触发里程碑及分成，对两家港股biotech的市值弹性明显高于AZN。
- 截至14:45 HKT，康诺亚（02162.HK）当日仍跌0.42%、乐普生物-B（02157.HK）仅涨0.68%，尚未看到对本次三期OS阳性的充分盘中重定价。
主要风险
- 试验PFS主要终点未达统计显著，仅显示改善趋势，后续监管沟通和医学会议完整数据可能削弱市场解读。
- 近期两只港股20日分别已涨约28.7%和23.2%，说明CLDN18.2/ADC管线可能已有部分预期，且授权条款中具体本次里程碑触发金额和未来利润分成节奏未能在当前窗口精确量化。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中可直接量化本次读出触发里程碑金额或分成节奏的高质量片段；这削弱仓位但不否定临床阳性方向。
检索:sonesitatug vedotin KYM Biosciences Keymed Lepu CLDN18.2 royalty milestone revenue - 做多前查反向 · 来源 web · 日期 2026-07-27 · 影响 weakens
公告同时披露二线及以上PFS主要终点未达统计显著，仅呈改善趋势，是本次做多的主要反证。
检索:Sone-Ve CLARITY-Gastric01 progression-free survival not statistically significant 原文 ↗
历史先例(按相似度)
- 相似度 8/10 3692 2026-07-10 翰森制药B7-H3 ADC HS-20093三期达到OS主要终点; event_study显示+1日+1.82%、+3日+2.69%、+5日-0.44%,次日高开后收低于开盘。 原文 ↗
事件后 +1日 +1.8% · +2日 +1.9% · +3日 +2.7% · +4日 +3.8% · +5日 -0.4%
相似度依据:同为港股肿瘤ADC三期OS阳性读数,但翰森收入/市值基数更大、弹性低于康诺亚/乐普权益链。 - 相似度 7/10 6990 2023-08-14 科伦博泰TROP2 ADC SKB264三期达到PFS主要终点; event_study显示+1日+2.74%、+3日+7.26%、+5日+16.44%,事件日明显高开低走后次日修复。 原文 ↗
事件后 +1日 +2.7% · +2日 +3.8% · +3日 +7.3% · +4日 +13.0% · +5日 +16.4%
相似度依据:同为港股ADC平台资产临床突破,但锚点是PFS主要终点而非OS,适应症也不同。 - 相似度 7/10 13 2022-08-08 和黄医药呋喹替尼全球III期FRESCO-2达到OS主要终点; event_study显示+1日-0.67%、+3日+0.67%、+5日-3.58%,反应偏平。 原文 ↗
事件后 +1日 -0.7% · +2日 -0.7% · +3日 +0.7% · +4日 -2.7% · +5日 -3.6%
相似度依据:同为港股创新药后线肿瘤三期OS阳性,但不是ADC且公司商业化/管线结构不同。 - 相似度 7/10 9926 2026-06-01 康方生物依沃西HARMONi-6在ASCO披露OS统计学显著阳性; event_study显示+1日-8.11%、+3日-14.19%、+5日-20.41%,事件日高开低走后继续下跌。 原文 ↗
事件后 +1日 -8.1% · +2日 -11.4% · +3日 -14.2% · +4日 -19.2% · +5日 -20.4%
相似度依据:同为港股创新药大适应症三期OS统计学显著阳性兑现,但为PD-1/VEGF双抗且此前预期抢跑较强。 - 相似度 7/10 CORT 2026-01-22 Corcept ROSELLA卵巢癌III期达到OS主要终点; event_study显示+1日+6.49%、+3日+11.91%、+5日+8.01%,方向明确为正。 原文 ↗
事件后 +1日 +6.5% · +2日 +10.5% · +3日 +11.9% · +4日 +11.0% · +5日 +8.0%
相似度依据:单资产价值重估型三期OS阳性最接近小中型biotech弹性,但非ADC、非中国创新药权益链。 - 相似度 6/10 9926 2025-09-07 康方生物/Summit依沃西HARMONi更新OS HR改善且名义p值显著; event_study显示+1日-1.68%、+3日-10.39%、+5日-9.54%,偏见光死。 原文 ↗
事件后 +1日 -1.7% · +2日 -6.3% · +3日 -10.4% · +4日 -4.9% · +5日 -9.5%
相似度依据:同为港股创新药授权资产海外关键III期OS数据更新,但属于更新/学会数据而非首次明确三期OS阳性公告。 - 相似度 6/10 MRK 2026-05-18 默沙东与科伦合作TROP2 ADC sac-TMT全球III期TroFuse-005达到OS和PFS主要终点; event_study显示+1日+1.49%、+3日+2.95%、+5日+6.36%。 原文 ↗
事件后 +1日 +1.5% · +2日 +0.4% · +3日 +3.0% · +4日 +8.8% · +5日 +6.4%
相似度依据:同为跨国药企合作ADC全球III期OS/PFS阳性,但测的是大型药企默沙东,权益和股价弹性被显著稀释。 - 相似度 5/10 GILD 2023-06-05 Gilead Trodelvy TROPiCS-02较长随访显示HR+/HER2-乳腺癌OS持续获益; event_study显示+1日-1.96%、+3日+0.87%、+5日+0.18%,次日高开低走。 原文 ↗
事件后 +1日 -2.0% · +2日 -2.1% · +3日 +0.9% · +4日 +0.5% · +5日 +0.2%
相似度依据:ADC生存期获益读数机制相关,但为已上市Trodelvy扩展随访数据且Gilead为大型药企,事件弹性较弱。
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- validate_order · 结果未知
原文全文
展开原文 · 2,349 字
Oil dives over 6% as easing U.S.-Iran tensions erase war-driven gains
CAMBRIDGE, UK - AstraZeneca (LSE/STO/NYSE:AZN) announced Sunday that sonesitatug vedotin demonstrated a statistically significant improvement in overall survival for patients with CLDN18.2-positive advanced gastric cancers in a Phase III trial, according to a press release statement.
The CLARITY-Gastric01 trial evaluated Sone-Ve in patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with CLDN18.2 expression on at least 25% of tumor cells. The trial met its dual primary endpoint of overall survival in third and later-line treatment and a key secondary endpoint of overall survival in the overall trial population of patients treated in the second and later-line setting.
The trial did not reach statistical significance for its other dual primary endpoint of progression-free survival as assessed by blinded independent central review in patients treated in the second and later-line setting, showing only a trend toward improvement.
The trial enrolled patients across 175 centers in 19 countries in North America, Europe, South America and Asia. Patients were randomized to receive Sone-Ve at 2.2 mg/kg or 1.8 mg/kg every three weeks, or investigator’s choice of therapy.
AstraZeneca stated that CLDN18.2 expression in 25% or more of tumor cells is found in approximately 60% of gastric/GEJ cancers. The company estimates roughly 183,500 patients annually in the US, EU, China and Japan are treated in the second and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.
Sone-Ve is an antibody drug conjugate targeting CLDN18.2 with a monomethyl auristatin E payload. AstraZeneca entered into a global exclusive license agreement with KYM Biosciences to develop and commercialize Sone-Ve in March 2023.
The drug has received Orphan Drug Designation from the US Food and Drug Administration and the European Commission for gastric and GEJ cancers, and Breakthrough Designation in China for second-line treatment of gastric cancer.
The company said results will be presented at a medical meeting and shared with global regulatory authorities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, UK - AstraZeneca (LSE/STO/NYSE:AZN) announced Sunday that sonesitatug vedotin demonstrated a statistically significant improvement in overall survival for patients with CLDN18.2-positive advanced gastric cancers in a Phase III trial, according to a press release statement.
The CLARITY-Gastric01 trial evaluated Sone-Ve in patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with CLDN18.2 expression on at least 25% of tumor cells. The trial met its dual primary endpoint of overall survival in third and later-line treatment and a key secondary endpoint of overall survival in the overall trial population of patients treated in the second and later-line setting.
The trial did not reach statistical significance for its other dual primary endpoint of progression-free survival as assessed by blinded independent central review in patients treated in the second and later-line setting, showing only a trend toward improvement.
The trial enrolled patients across 175 centers in 19 countries in North America, Europe, South America and Asia. Patients were randomized to receive Sone-Ve at 2.2 mg/kg or 1.8 mg/kg every three weeks, or investigator’s choice of therapy.
AstraZeneca stated that CLDN18.2 expression in 25% or more of tumor cells is found in approximately 60% of gastric/GEJ cancers. The company estimates roughly 183,500 patients annually in the US, EU, China and Japan are treated in the second and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.
Sone-Ve is an antibody drug conjugate targeting CLDN18.2 with a monomethyl auristatin E payload. AstraZeneca entered into a global exclusive license agreement with KYM Biosciences to develop and commercialize Sone-Ve in March 2023.
The drug has received Orphan Drug Designation from the US Food and Drug Administration and the European Commission for gastric and GEJ cancers, and Breakthrough Designation in China for second-line treatment of gastric cancer.
The company said results will be presented at a medical meeting and shared with global regulatory authorities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。